Federal grant · project grant (b)
Regenerative Peptide Therapy to Accelerate Pressure Ulcer Healing - Abstract Adrenomedullin (ADM) and CGRP Family Peptides Play Pivotal Roles in Regulating Angiogenesis, Vasculogenesis, and Tissue Regeneration. Although Wild-type Adm and CGRP Improve Wound Healing in a Variety of Injury Models, They Are Poor Drug Candidates for the Chronic Treatment of Different Disorders. Our Recent Study of Super-agonistic Adm Analogs, Which Self-assemble to Form Liquid Nanogels in Situ, Suggested These Analogs Are Ideal Candidates for Mitigating Tissue Damage and Accelerating Wound Healing in Patients With Bed Sores or Nonhealing Pressure Ulcers. Notably, the Self-assembled Analog Gel Has a 100% Loading Capacity and Allows Localized Treatment via Its Multi-faceted Regenerative Actions. Ideally, the Proposed Analog Gel Therapy Would Be Administered Weekly or Biweekly Subcutaneously in the Wound Area to Improve Local Blood Circulation and Accelerate Wound Healing. the Specific Aims of This Phase I Study Include Identifying an Ideal Analog Gel Formulation and Dose Range That Promotes Vascular Bed Circulation But Avoids an Effect on Systemic Hemodynamics in Aging Diabetic Mice (aim 1). Once the Ideal Analog Gel Is Identified, We Will Evaluate Whether the Analog Gel Treatment Correlates With Enhanced Healing Functions in Aging Mice With Hindlimb Ischemia Injury or Pressure-induced Skin Ulcers. We Will Also Compare the Analog Gel With PDGF, the Only Fda-approved Growth Factor for Wound Care, Thereby Completing the Lead Optimization Process.
Committed
$367,577
Paid out
$357.0K
97%
Committed, not yet paid
$10.6K
3%
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then .
Loading…